Prospective Grant of an Exclusive Patent License: The Development of Autologous Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) T Cell Receptor (TCR) for the Treatment of KK-LC-1 Expressing Human Cancer, 71969 [2019-28150]
Download as PDF
Federal Register / Vol. 84, No. 249 / Monday, December 30, 2019 / Notices
US–06], and U.S. and foreign patent
applications claiming priority to the
aforementioned applications.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: The Development of
Autologous Kita-Kyushu Lung Cancer
Antigen 1 (KK–LC–1) T Cell Receptor
(TCR) for the Treatment of KK–LC–1
Expressing Human Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to T-Cure
Biosciences, Inc. (T-Cure), located in
Sherman Oaks, California.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before January 14, 2020 will be
considered.
SUMMARY:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Abritee Dhal, Ph.D.,
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 3W610 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702, Telephone: (240) 276–6154;
Facsimile: (240) 276–5504; Email:
abritee.dhal@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
khammond on DSKJM1Z7X2PROD with NOTICES
Intellectual Property
U.S. Provisional Patent Application
62/327,529 entitled ‘‘Anti-KK–LC–1 T
Cell Receptors’’ [HHS Ref. E–153–2016–
0–US–01], PCT Patent Application PCT/
US2017/027865 entitled ‘‘Anti-KK–LC–
1 T Cell Receptors’’ [HHS Ref. E–153–
2016–0–PCT–02], Australian Patent
Application 2017258745 entitled ‘‘AntiKK–LC–1 T Cell Receptors’’ [HHS Ref.
E–153–2016–0–AU–03], Canadian
Patent Application 3021898 entitled
‘‘Anti-KK–LC–1 T Cell Receptors’’ [HHS
Ref. E–153–2016–0–CA–04], European
Patent Application 1733120.4 entitled
‘‘Anti-KK–LC–1 T Cell Receptors’’ [HHS
Ref. E–153–2016–0–EP–05], United
States Patent Application 16/096,118,
entitled ‘‘Anti-KK–LC–1 T Cell
Receptors’’ [HHS Ref. E–153–2016–0–
VerDate Sep<11>2014
20:00 Dec 27, 2019
Jkt 250001
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to:
The development, manufacture and
commercialization of autologous
(meaning one individual is both the
donor and the recipient), peripheral
blood T cell therapy products
engineered by retrovirus (including
lentivirus) to express T cell receptors
(TCR) reactive to Kita-Kyushu Lung
Cancer Antigen 1 (KK–LC–1) wherein
the TCR has:
1. A single antigen specificity; and
2. a binding domain with
complementary determining region
(CDR) sequences of
CASSLGTGGYNEQFF (beta chain) and
CAGQLVYGNKLVF (alpha chain); for
the treatment of KK–LC–1 expressing
cancers.
This technology discloses TCRs that
are specific for the cell surface domain
of KK–LC–1. The TCRs can potentially
be used for the treatment of triple
negative breast cancer, gastric cancer,
and lung cancer. In the subject situation,
the TCRs can lead to the selective
destruction of the cancerous cells.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
71969
Dated: December 19, 2019.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2019–28150 Filed 12–27–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Transcatheter Trileaflet Tricuspid Suture
Repair System—Phase II.
Date: January 21, 2020.
Time: 11:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: NIH RKL II, 6701 Rockledge Drive,
Bethesda, MD 21892 (Telephone Conference
Call).
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, 301–435–0725,
kristen.page@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: December 23, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–28153 Filed 12–27–19; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 84, Number 249 (Monday, December 30, 2019)]
[Notices]
[Page 71969]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-28150]
[[Page 71969]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: The Development
of Autologous Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) T Cell
Receptor (TCR) for the Treatment of KK-LC-1 Expressing Human Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the SUPPLEMENTARY INFORMATION section of this notice to T-Cure
Biosciences, Inc. (T-Cure), located in Sherman Oaks, California.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before January 14, 2020 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Abritee Dhal, Ph.D., Technology Transfer
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM
3W610 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville,
MD 20850-9702, Telephone: (240) 276-6154; Facsimile: (240) 276-5504;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
U.S. Provisional Patent Application 62/327,529 entitled ``Anti-KK-
LC-1 T Cell Receptors'' [HHS Ref. E-153-2016-0-US-01], PCT Patent
Application PCT/US2017/027865 entitled ``Anti-KK-LC-1 T Cell
Receptors'' [HHS Ref. E-153-2016-0-PCT-02], Australian Patent
Application 2017258745 entitled ``Anti-KK-LC-1 T Cell Receptors'' [HHS
Ref. E-153-2016-0-AU-03], Canadian Patent Application 3021898 entitled
``Anti-KK-LC-1 T Cell Receptors'' [HHS Ref. E-153-2016-0-CA-04],
European Patent Application 1733120.4 entitled ``Anti-KK-LC-1 T Cell
Receptors'' [HHS Ref. E-153-2016-0-EP-05], United States Patent
Application 16/096,118, entitled ``Anti-KK-LC-1 T Cell Receptors'' [HHS
Ref. E-153-2016-0-US-06], and U.S. and foreign patent applications
claiming priority to the aforementioned applications.
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to:
The development, manufacture and commercialization of autologous
(meaning one individual is both the donor and the recipient),
peripheral blood T cell therapy products engineered by retrovirus
(including lentivirus) to express T cell receptors (TCR) reactive to
Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) wherein the TCR has:
1. A single antigen specificity; and
2. a binding domain with complementary determining region (CDR)
sequences of CASSLGTGGYNEQFF (beta chain) and CAGQLVYGNKLVF (alpha
chain); for the treatment of KK-LC-1 expressing cancers.
This technology discloses TCRs that are specific for the cell
surface domain of KK-LC-1. The TCRs can potentially be used for the
treatment of triple negative breast cancer, gastric cancer, and lung
cancer. In the subject situation, the TCRs can lead to the selective
destruction of the cancerous cells.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: December 19, 2019.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2019-28150 Filed 12-27-19; 8:45 am]
BILLING CODE 4140-01-P